Parallel Health World News Logo

Parallel Health World

cropper
  • Home
  • Categories
    • EcoHealth Trends
    • Healing Naturally
    • Age-Defying Diets
    • Supplement Savvy
    • Mind-Body Synergy
    • Finance and Health
    • Biolimitless
    • Tech Hacks
    • Health & Medicine
    • Political
    • BioBuzz
    • Holistic Rehabilitation Techniques
    • Practitioner Insights
    • AI In Healthcare
  • Featured Business Profiles
November 20.2026
3 Minutes Read

Hemostemix's Promising Approach to Longevity Treatments Explained

Plain black square associated with Hemostemix longevity treatment.

The Future of Longevity Treatments: Innovations on Display

In the ever-evolving field of biotechnology, Hemostemix Inc. stands on the threshold of significant advancements in longevity treatments. At the Small Cap Growth Virtual Investor Conference, President and CEO Thomas Smeenk will present insights on the company’s Phase I clinical trials for their groundbreaking treatment aimed at extending healthspan—the period of life spent in good health. As life expectancy rises globally, with projections indicating that by 2050, over 2 billion people will be aged 60 or older, the demand for effective longevity solutions has never been greater. The implications of this shift could redefine healthcare systems, pushing for more innovations in treatment aimed at improving quality of life among senior citizens.

Why Invest in Hemostemix Now?

During Smeenk's presentation at 12:00 p.m. Eastern Time, he will emphasize the pressing need for potential investments in Hemostemix at its current market valuation. Recent studies indicate that longevity treatments could become a $40 billion market by 2026, bolstered by an aging population and increasing healthcare awareness. With such promising forecasts, investing in Hemostemix not only presents an opportunity for financial return but also contributes to a healthier society. By positioning itself strategically now, stakeholders may benefit from the potential growth in this burgeoning sector, as individuals and families prioritize investment in healthspan along with lifespan.

Understanding Hemostemix's Groundbreaking Approach

Hemostemix is pioneering a novel approach that harnesses the body's natural regenerative capabilities. The Phase I trials focus on utilizing patented stem cell technologies to enhance cellular function, thereby increasing the body's ability to repair and rejuvenate tissues. This revolutionary treatment could redefine how we approach aging, shifting the focus from treatment of age-related diseases to prevention and enhancement of health at every stage of life. Such a paradigm shift emphasizes proactive health management, allowing individuals to maintain vitality and well-being longer, rather than simply prolonging life in a diminished state.

Healthcare Trends: The Rise of Preventative Care

The relevance of Hemostemix’s innovations cannot be overstated in light of the current trend toward preventative healthcare. Patients are increasingly seeking treatments that not only address illnesses but also promote wellness and longevity. The efficacy of Hemostemix’s treatment could position the company at the forefront of a paradigm shift in healthcare—from reactive to proactive, giving individuals more control over their health outcomes. As the landscape of healthcare transforms, innovations like those from Hemostemix may lead to a new era where maintaining health becomes prioritized as much as restoring it after deterioration.

Potential Challenges and Counterarguments

While the promise of longevity treatments is enticing, skeptics argue about the scalability and accessibility of such technologies. Concerns about regulatory hurdles and the ethical implications of biotechnology in addressing aging are valid discussions that need consideration. Hemostemix, however, appears to be navigating these complexities with a clear strategy, demonstrating transparency in its research and commitment to ethical practices. Moreover, as new technologies develop, they often face scrutiny; however, collaboration with regulatory bodies and ethical review boards can help ensure that these advancements benefit a broad population while maintaining public trust.

Real-world Impact: Potential to Transform Lives

The practical implications of Hemostemix’s work extend beyond investor interest; they hold the potential to transform lives and improve overall societal health. By focusing on enhancing the body's natural repair mechanisms, their research may offer solutions to age-related ailments that afflict millions, thereby reducing the burden on healthcare systems. If successful, such treatments could lead to increased productivity, lower healthcare costs for chronic conditions, and a more vibrant population that contributes to economic growth.

Call to Action: Engage with Innovative Healthcare Solutions

As Hemostemix strives to lead in the field of longevity treatments, interested parties should seize the opportunity to learn more about their initiatives. Investing in companies that prioritize innovation in healthcare can foster advancements that benefit society at large. Engage with Hemostemix at the conference and explore how their efforts can pave the way for transformative healthcare solutions. This is not just an opportunity for potential financial gains; it’s a chance to be part of something that could radically enhance quality of life for future generations. The innovations in biotechnology represent not just scientific progress but a beacon of hope for countless individuals seeking healthier, longer lives.

Biolimitless

3 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
11.21.2026

Understanding BetterLife Pharma's Market Maker Engagement: A Strategic Move for Investors

Update Market Making for Biotechnology: Why It MattersBetterLife Pharma Inc., based in Vancouver, specializes in innovative solutions for chronic headache disorders. By engaging Integral Wealth Securities Limited for market-making services, BetterLife is establishing a foothold in the biotechnology sector. This partnership is not merely a financial transaction; it strategically positions the company for better liquidity, enhancing visibility among investors.Market-making is essential in biotech, where investor confidence can significantly impact company valuations. The engagement with Integral aims to not only stabilize but also potentially increase the trading volume of BetterLife shares. This is crucial for companies that rely heavily on public perception and market activity. Increased liquidity can reduce volatility, making investors more comfortable with their holdings.The Innovations Behind BETR-001At the heart of BetterLife's endeavors is BETR-001, a promising treatment for chronic cluster headaches and migraines. The drug, currently in development, aims to provide relief for millions suffering from these debilitating conditions. Approaches in biotechnology like this are rapidly evolving, especially as new understandings of neurological conditions emerge.Clinical trials are arduous, but they are essential for ensuring safety and efficacy. As BetterLife moves through these phases, market support—like that from Integral—can encourage investment at various stages, allowing companies to focus on research rather than financial uncertainties.The Role of Market Makers in Volatile MarketsMarket makers play a vital role in financial ecosystems, especially within niche sectors like biotechnology. Their job involves ensuring that there's a buyer for every seller, thereby facilitating smoother transactions. In volatile markets, such as those driven by breakthrough medical advancements, this can significantly impact investor sentiment.Moreover, in cases where stocks may swing wildly due to news or earnings reports, effective market-making helps maintain fair pricing. For BetterLife Pharma, with its significant potential in the healthcare sector, partnering with a skilled market maker is an intelligent move that may bolster investor trust.Investor Perspectives on BiotechnologyInvestors considering biotech stocks must weigh the inherent risks against potential rewards. With substantial investments often needed for research and development, profitability can often feel like a distant goal. However, as with BetterLife, companies that achieve successful product milestones frequently see enhanced stock valuations.As the market matures, the demand for innovative treatments continues to grow. This creates a fertile environment for biotech ventures. The success of treatments like BETR-001 could pave the way for further advancements, supporting the idea that investing in biotech, while risky, can also yield substantial returns for those who strategically market their innovations.Future Prospects for BetterLifeLooking forward, BetterLife's decision to engage Integral Wealth Securities Limited could be a pivotal moment in its operational strategy. It signifies a commitment to transparency and stability, key attributes that investors often prioritize. Should clinical trials for BETR-001 progress positively, the backing of an effective market maker could position BetterLife to attract more significant interest from both institutional and retail investors.This synergy between effective market strategies and innovative treatments underlines a crucial trend in the biotech industry: the confluence of finance and health innovations. As the landscape evolves, companies that effectively harness this relationship may find themselves at the forefront of market advancements, shaping not just their financial future but also the health of countless individuals.

11.19.2026

Doseology’s Annual General Meeting Results: What It Means for Biotechnology Innovations

Update A Turning Point for Doseology: Key Results from the Annual MeetingOn November 18, 2026, Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70), a pioneering force in biotechnology solutions, convened its annual general meeting in Kelowna, British Columbia. This year’s meeting was particularly noteworthy as it reflected an increased engagement among shareholders, with a total of 2,824,597 common shares voted, constituting approximately 34.93% of its issued and outstanding shares. This marked an encouraging trend for the company as it works to foster a more connected and engaged shareholder base.Your Voice Matters: Shareholder ParticipationThe heightened voter turnout suggests a growing confidence from the shareholders in Doseology’s strategy and future direction. At the core of this annual gathering was the company's strategic roadmap and its aim to push the boundaries of innovation in its field. The outcomes of the Meeting are crucial, as they lay the groundwork for the Company's trajectory in 2027 and beyond. This increased participation may be reflective of the overall sentiment in the biotechnology sector, where investors are seeking companies that not only innovate but also involve their stakeholders in vital decision-making processes. This collaborative approach can lead to a more transparent and accountable company, ultimately benefiting its long-term sustainability and growth.Unlocking Progress: Key Themes from the MeetingAmong the approved resolutions, shareholders focused on several key initiatives aimed at expanding Doseology's impact in biotechnology and health solutions. One of the prominent proposals was an enhancement in research and development efforts, particularly in areas that intersect with artificial intelligence and bioinformatics—fields where Doseology aims to excel. By fostering an environment ripe for innovation, Doseology is positioning itself to tackle current health challenges more efficiently.Furthermore, the approval of these initiatives represents not just a nod to the importance of R&D but also an acknowledgment of the need for diversified approaches in addressing healthcare issues. As healthcare challenges grow increasingly complex, the combination of AI and biotechnology may prove crucial in developing personalized treatments and interventions that are tailored to individual patient needs.Looking Forward: Industry Outlook and InnovationThe biotechnology sector is poised for transformative changes as new technologies emerge, particularly in AI and data analytics. This is a crucial time for Doseology as it seeks to capitalize on these developments, ensuring that it remains competitive in the market. The company's commitment to harnessing these technologies echoes a broader trend in the industry: the integration of computational methodologies into biological research. This could enhance how health systems operate, creating more personalized and effective care models.Experts note that the intersection of AI and biotechnology could lead to groundbreaking discoveries that redefine patient care. As the industry shifts towards a more data-driven approach, Doseology’s potential to contribute innovative solutions is noteworthy, especially at a time when health systems are under pressure to improve efficiency while managing costs.Community Perspectives: The Human ElementAs Doseology embarks on its mission to merge health sciences with innovative technologies, it is crucial to consider the community's perspective. Many stakeholders, from patients to health professionals, are eager for advancements that improve the quality of care. There is a palpable desire for solutions that not only address symptoms but also improve overall wellness and health resilience.As the company develops solutions that align with holistic health practices and mind-body synergy, the social impact becomes a focal point. Engaging with communities not only broadens the company’s vision but also ensures that these innovations meet real-world needs. Public forums, community outreach, and collaborations with healthcare providers could pave the way for Doseology to fine-tune its offerings to better serve diverse populations.Conclusion: A Call to Stay Informed and EngagedThe results of Doseology’s Annual General Meeting mark a significant milestone for the company and its shareholders. It is vital for interested parties to stay informed about Doseology’s developments, especially as they lead the charge towards integrating technology with health solutions. Keeping a pulse on these advancements can provide invaluable insights into the evolving landscape of healthcare and biotechnology.For those invested or considering an investment, these conversations and outcomes are not just numbers; they indicate the evolving landscape of healthcare and biotechnology. Observing how Doseology adapts to emerging trends and responds to stakeholder feedback will prove essential in understanding its long-term viability and impact on the industry.

10.16.2026

Exploring BetterLife Pharma's Legal Challenge: What Could It Mean for Investors?

Update Understanding the Legal Dispute: What Happened?BetterLife Pharma Inc., a biotechnology company known for its innovative research in neurological disorders, is facing a significant legal challenge following a Notice of Civil Claim filed by Steven Sangha, an independent director of the company. The claim, lodged in the Supreme Court of British Columbia on October 8, 2026, stems from a dispute over a convertible debenture issued to Sangha in June 2026. This debenture has become the focal point of contention, with the director seeking to convert it into a substantial number of common shares and purchase warrants. The Background: Assessing The ClaimsCentral to this legal struggle is the principal amount of the convertible debenture that Sangha alleges is owed to him. According to prior financial statements, BetterLife had indicated that they were in discussions to resolve the matter amicably. However, it appears the negotiations did not reach a satisfactory conclusion, prompting Sangha to take legal recourse. This unexpected turn of events not only raises questions about the company’s internal governance but also hints at potential financial distress or mismanagement, making it critical for stakeholders to stay informed. Analyzing the Corporate ResponseIn response to the civil claim, BetterLife announced that it intends to defend itself vigorously, emphasizing its commitment to managing this situation through appropriate legal channels. This proactive approach aims to reassure investors and the public that the company considers this matter resolvable and valid in light of its broader operational objectives. Such responses are paramount in maintaining investor confidence, especially in a sector like biotechnology, where innovative projects like BETR-001 are underway to treat conditions like chronic migraines and cluster headaches. The Implications for the Company and Its StakeholdersThis legal situation could have several ramifications for BetterLife Pharma. Firstly, it could affect the company’s public image, especially among investors who might be concerned about the company's financial stability and governance practices. A successful resolution may restore faith among stakeholders, but a prolonged legal battle could deter potential investors and harm business partnerships. Moreover, as better funding and corporate reputation are vital in the biotech arena, how BetterLife navigates this dispute will likely influence its future project developments and strategic direction. BetterLife’s Aspirations in Biotechnology: The Road AheadAs this legal battle unfolds, it is crucial to remember that BetterLife remains focused on advancing its primary objective—developing BETR-001. This investigational drug, derived from a non-hallucinogenic compound, aims to address the unmet medical need for effective migraine treatment. With a secured U.S. patent covering BETR-001, the company is positioned well for future growth, provided that it can effectively manage its current legal disputes and continue to drive its innovative projects forward. Looking Forward: What’s Next for BetterLife?Stakeholders and observers are keenly watching how BetterLife will deal with this issue and what implications it will have for its business trajectory. The biotechnology landscape is fraught with rapid changes and challenges; how the company handles this claim will set the tone for its resilience and adaptability moving forward. Potential advances in their therapeutic solutions depend not just on research but also on the company's strategic handling of internal conflicts like this one. ConclusionThe situation with Steven Sangha's civil claim is critical for BetterLife Pharma, and its management will need to act swiftly and judiciously to navigate these murky waters. As they strive to balance legal obligations with their groundbreaking pursuits in biotechnology, issues such as transparency, governance practices, and communication will play as significantly as the company's scientific advancements. Stakeholders should remain vigilant and informed as this case progresses and consider its potential impacts on the broader biotechnology industry.

Where Conventional Meets Natural for a Healthier You

Parallel Health World News offers clarity and actionable knowledge for those eager to harmonize the best of both medical worlds, helping its audience achieve a truly integrative approach to health and wellness.

Advertise
Parallel Health World News
SeamanDan.com
Dan Seaman Media Press Pass

ABOUT US
SeamanDan LLC is a modern news media agency creating niche digital channels that inform and engage. We specialize in launching focused platforms that deliver impactful content.  Our current brands include:
Parallel Health World
AI Insights Hub
MLM News AI
Rider Safe News
Meme Crypto News
Rugged Trails Network
Recreation Wave
Outdoor Odyssey News
Eco-Innovation Hub
Metal Green Innovators
Autism Foundation News

At SeamanDan LLC, we don't just report the news we create platforms that build communities, foster trust, and drive forward-thinking conversations.  Can we build a channel for you?

© 2026 Parallel Health World News All Rights Reserved. 810 N Main St #187, Spearfish, SD 57783 . Contact Us . Terms of Service . Privacy Policy

{"company":"Parallel Health World News","address":", ,  ","city":"","state":"","zip":"","email":"seamandan@seamandan.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*